Scarica l'app Stockscreener
98.06
0.33%
0.94
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
Enterprise value to EBIT forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Monopar Therapeutics: ALXN1840's Bull Case Has Improved (NASDAQ:MNPR) - Seeking Alpha
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Monopar Therapeutics (MNPR) CFO nets shares from RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) CEO nets shares after RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) COO gains stock via RSU vesting and tax withholding - Stock Titan
Liquidity Mapping Around (MNPR) Price Events - Stock Traders Daily
Monopar Therapeutics price target raised to $117 from $104 at BTIG - TipRanks
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $117 - Moomoo
MNPR Maintained by BTIG -- Price Target Raised to $117 - GuruFocus
Form 4 Monopar Therapeutics Inc For: 30 June By Investing.com - Investing.com India
Monopar Therapeutics (MNPR) director granted 1,284 stock options - Stock Titan
Monopar Therapeutics (MNPR) director Nicole Sweeny files initial Form 3 - Stock Titan
Monopar gets rare pediatric disease tag for Wilson treatment - Investing.com UK
Monopar Therapeutics (MNPR) Receives FDA Rare Pediatric Disease Designation - GuruFocus
Monopar Therapeutics Inc. Granted FDA Rare Pediatric Disease Designation – Official SEC 8-K Filing June 30, 2026 - Minichart
Monopar Wins FDA Rare Pediatric Disease Designation - TipRanks
Monopar stock jumps after FDA rare pediatric disease tag By Investing.com - Investing.com India
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease - The Manila Times
FDA grants Rare Pediatric Disease designation to Monopar (MNPR) Wilson disease drug ALXN1840 - Stock Titan
FDA rare pediatric disease tag could speed ALXN1840’s path for Wilson disease - Stock Titan
BTIG raises Monopar Therapeutics price target on regulatory outlook - Investing.com
BTIG raises Monopar Therapeutics price target on regulatory outlook By Investing.com - Investing.com Canada
+8.47% for Monopar Therapeutics stock as buyers push price above key averages - Traders Union
Monopar Therapeutics Inc Actuals & Estimates (NASDAQ:MNPR) - TradingView
H.C. Wainwright reiterates Monopar stock rating on trial data By Investing.com - Investing.com India
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - Moomoo
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 2000 Value Benchmark - marketscreener.com
H.C. Wainwright reiterates Monopar stock rating on trial data - Investing.com UK
Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Microcap Value Benchmark Index - marketscreener.com
MNPR Reiterates by HC Wainwright & Co. -- Price Target Maintained at $105 - GuruFocus
Monopar Therapeutics Insiders Make Handsome Sum Selling Stock At US$67.15 Per Share - simplywall.st
Price to earnings forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Price to book forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Enterprise value to EBITDA forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Enterprise value to revenue forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Enterprise value to revenue forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Price to sales forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Price to earnings forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Monopar plans mid-2026 NDA filing for Wilson disease drug - Investing.com UK
MNPR Forecast — Price Target — Prediction for 2027 - TradingView
Monopar Highlights Positive Phase 3 Wilson Disease Data - TipRanks
Monopar Therapeutics (MNPR) to Present New Data on ALXN1840 at E - GuruFocus
Monopar Presents Phase 3 FoCus Data Showing Neurologic and Global Benefit with ALXN1840 - TradingView
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease - The Manila Times
ALXN1840 Phase 3 data back NDA plan for Wilson disease, Monopar (NASDAQ: MNPR) - Stock Titan
Monopar Therapeutics Inc Actuals & Estimates (LS:A40JML) - TradingView
Monopar Therapeutics Inc Actuals & Estimates (DUS:1IY0) - TradingView
A40JML Forecast — Price Target — Prediction for 2027 - TradingView
1IY0 Forecast — Price Target — Prediction for 2027 - TradingView
NDA submission progress for ALXN1840 in Wilson disease sends Monopar Therapeutics stock up 7.61% - Traders Union
Monopar Therapeutics Inc Cash Flow – DUS:1IY0 - TradingView
Monopar Therapeutics Surges 18%: Biotech Momentum Builds Past Key ResistanceMFI Divergence - dars.gov.et
Near-term momentum pushes Monopar Therapeutics stock up 7.19% - Traders Union
Monopar Therapeutics shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
Monopar Therapeutics shareholders approve all proposals at annual meeting - Investing.com
Monopar Shareholders Approve Directors, Pay and Incentive Plan - TipRanks
1.16%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):